USMLE Step 3 Quiz: Chronic Liver Disease And Cirrhosis Care

What this quiz covers

This quiz focuses on Chronic Liver Disease And Cirrhosis Care, giving you a quick way to practice the rules, question types, and explanations that matter most for USMLE Step 3.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

Question 1

1. Start IV ceftriaxone for spontaneous bacterial peritonitis (correct answer)
2. Begin propranolol immediately to prevent variceal bleeding
3. Order CT abdomen with contrast before initiating therapy
4. Increase dietary protein restriction to <20 g/day

Explanation: This question tests the management of chronic liver disease and cirrhosis, focusing on clinical decision-making appropriate for independent practice. Chronic liver disease requires careful monitoring and management of complications such as ascites, hepatic encephalopathy, and variceal bleeding. In this vignette, the patient's confusion, asterixis, and paracentesis with PMN 320 cells/mm³ suggest spontaneous bacterial peritonitis precipitating encephalopathy, requiring immediate assessment and treatment to prevent complications. The correct choice, starting IV ceftriaxone for spontaneous bacterial peritonitis, reflects the appropriate initial management step, aligning with current guidelines for managing cirrhosis and its complications. A common distractor choice, beginning propranolol immediately to prevent variceal bleeding, fails because it suggests a non-standard treatment, highlighting a common misconception about liver disease management. To aid learning, emphasize the importance of lifestyle modifications and regular monitoring of liver function to manage and prevent progression of cirrhosis. Encourage the practice of applying standardized guidelines to diverse clinical scenarios.

Question 2

1. Ultrasound of the liver every 6 months with or without AFP (correct answer)
2. CT abdomen with contrast monthly for early detection
3. No surveillance is needed after hepatitis C cure
4. PET scan annually to screen for metastatic disease

Explanation: This question tests the management of chronic liver disease and cirrhosis, focusing on clinical decision-making appropriate for independent practice. Chronic liver disease requires careful monitoring and management of complications such as ascites, hepatic encephalopathy, and variceal bleeding. In this vignette, the patient's cirrhosis and risk for hepatocellular carcinoma suggest need for surveillance, requiring immediate assessment and treatment to prevent complications. The correct choice, ultrasound of the liver every 6 months with or without AFP, reflects the appropriate initial management step, aligning with current guidelines for managing cirrhosis and its complications. A common distractor choice, no surveillance is needed after hepatitis C cure, fails because it suggests a non-standard treatment, highlighting a common misconception about liver disease management. To aid learning, emphasize the importance of lifestyle modifications and regular monitoring of liver function to manage and prevent progression of cirrhosis. Encourage the practice of applying standardized guidelines to diverse clinical scenarios.

Question 3

1. Start long-term SBP prophylaxis with oral antibiotic therapy (correct answer)
2. Stop diuretics permanently and rely on serial paracenteses only
3. Begin chronic prednisone to suppress peritoneal inflammation
4. No prophylaxis is needed if symptoms resolve

Explanation: This question tests the management of chronic liver disease and cirrhosis, focusing on clinical decision-making appropriate for independent practice. Chronic liver disease requires careful monitoring and management of complications such as ascites, hepatic encephalopathy, and variceal bleeding. In this vignette, the patient's history of SBP suggests need for prophylaxis, requiring immediate assessment and treatment to prevent complications. The correct choice, starting long-term SBP prophylaxis with oral antibiotic therapy, reflects the appropriate initial management step, aligning with current guidelines for managing cirrhosis and its complications. A common distractor choice, no prophylaxis is needed if symptoms resolve, fails because it suggests a non-standard treatment, highlighting a common misconception about liver disease management. To aid learning, emphasize the importance of lifestyle modifications and regular monitoring of liver function to manage and prevent progression of cirrhosis. Encourage the practice of applying standardized guidelines to diverse clinical scenarios.

Question 4

1. Initiate therapy with nadolol.
2. Perform prophylactic endoscopic band ligation.
3. Repeat endoscopy in 1 to 2 years. (correct answer)
4. Start a daily high-dose proton pump inhibitor.

Explanation: Current guidelines for primary prophylaxis of variceal bleeding recommend that patients with compensated cirrhosis and small varices without high-risk stigmata (e.g., red wale signs) do not require immediate treatment with non-selective beta-blockers or band ligation. The recommended approach is surveillance with a repeat EGD in 1-2 years to monitor for an increase in variceal size, which would then prompt initiation of prophylactic therapy. Beta-blockers are typically reserved for medium/large varices or decompensated cirrhosis.

Question 5

1. No long-term prophylaxis is indicated at this time.
2. Initiate long-term prophylaxis with daily ciprofloxacin. (correct answer)
3. Repeat paracentesis in one week to re-evaluate the cell count.
4. Treat with a 7-day course of ceftriaxone for subacute SBP.

Explanation: The patient's ascitic fluid PMN count is 45 cells/mm³ (150 * 0.30), which is below the diagnostic threshold for SBP (>250 cells/mm³). However, long-term SBP prophylaxis is indicated in patients with ascites who have a low ascitic fluid protein concentration (<1.5 g/dL) because this indicates a deficit in ascitic fluid opsonic activity, increasing infection risk. This patient's protein is 0.8 g/dL, meeting the criteria for primary prophylaxis. Daily ciprofloxacin or norfloxacin is a standard regimen.

Question 6

1. Repeat ultrasound and AFP in 3 months.
2. Obtain a multiphasic contrast-enhanced CT or MRI of the liver. (correct answer)
3. Proceed with percutaneous biopsy of the liver lesion.
4. Refer the patient for transarterial chemoembolization (TACE).

Explanation: For a newly detected liver lesion between 1 and 2 cm in a cirrhotic patient, the standard diagnostic algorithm requires further characterization with multiphasic cross-sectional imaging (either a 4-phase CT or dynamic contrast-enhanced MRI). These studies can identify the characteristic vascular features of hepatocellular carcinoma (HCC), such as arterial phase hyperenhancement and venous/delayed phase washout, which can be diagnostic without a biopsy. Repeating the ultrasound is an unacceptable delay, biopsy is reserved for indeterminate lesions on cross-sectional imaging, and TACE is a treatment, not a diagnostic step.

Question 7

1. Spontaneous bacterial peritonitis.
2. Medication non-adherence.
3. Constipation. (correct answer)
4. Gastrointestinal bleeding.

Explanation: The patient presents with signs of overt hepatic encephalopathy (HE). In patients with known cirrhosis, it is crucial to identify and treat the precipitating cause. Common precipitants include infection (e.g., SBP), GI bleeding, electrolyte disturbances, new psychoactive medications, and constipation. The history explicitly mentions four days of constipation, which leads to increased intestinal production and absorption of ammonia, making it the most likely cause in this scenario.

Question 8

1. Referral for transjugular intrahepatic portosystemic shunt (TIPS) evaluation. (correct answer)
2. Addition of midodrine to her current medication regimen.
3. Initiation of scheduled salt-poor albumin infusions twice weekly.
4. Placement of a permanent indwelling peritoneal drainage catheter.

Explanation: This patient has refractory ascites. The primary treatment options are serial large-volume paracentesis (LVP) or TIPS. Since she is already requiring frequent LVP, TIPS is the definitive next step to consider for long-term control. It decompresses the portal system, reducing ascites formation. In a patient with a reasonable MELD score and no history of encephalopathy, TIPS is an excellent option. Midodrine is for HRS, albumin infusions are not a standard long-term strategy, and indwelling catheters have a very high infection risk.

Question 9

1. Acetaminophen, up to 2 grams per day.
2. Naproxen. (correct answer)
3. Tramadol.
4. Topical capsaicin cream.

Explanation: Non-steroidal anti-inflammatory drugs (NSAIDs) like naproxen should be avoided in patients with cirrhosis. NSAIDs inhibit prostaglandin synthesis, which is critical for maintaining renal blood flow in the setting of portal hypertension and splanchnic vasodilation. Their use can precipitate acute kidney injury and hepatorenal syndrome. They also increase the risk of gastrointestinal bleeding. Acetaminophen is safe at reduced doses (≤2 g/day), tramadol can be used cautiously, and topical agents are safe.

Question 10

1. Portopulmonary hypertension.
2. Hepatic hydrothorax.
3. Hepatopulmonary syndrome. (correct answer)
4. Interstitial lung disease.

Explanation: The patient's clinical presentation is classic for hepatopulmonary syndrome (HPS). The pathognomonic finding is platypnea-orthodeoxia: dyspnea (platypnea) and hypoxemia (orthodeoxia) that are worse in the upright position and improve with lying down. This occurs due to intrapulmonary vascular dilatations that are most pronounced at the lung bases, leading to increased shunting and V/Q mismatch in the upright posture. Hepatic hydrothorax would cause dyspnea but not the positional desaturation, and portopulmonary hypertension presents with signs of right heart failure.

Question 11

1. Administration of 3% hypertonic saline.
2. Discontinuation of all diuretic medications.
3. Initiation of a vasopressin receptor antagonist.
4. Restriction of free water intake to 1.5 liters per day. (correct answer)

Explanation: This patient has asymptomatic hypervolemic hyponatremia, a common complication of advanced cirrhosis caused by non-osmotic release of antidiuretic hormone (ADH), leading to impaired free water excretion. The cornerstone of initial management is restricting free water intake (typically to 1-1.5 L/day). Hypertonic saline is reserved for severe, symptomatic cases. Discontinuing diuretics could worsen ascites, and vasopressin antagonists (vaptans) are second-line agents due to cost and risk of overly rapid correction.

Question 12

1. Place a transjugular intrahepatic portosystemic shunt for his refractory ascites.
2. Arrange a formal palliative care consultation to clarify goals of care. (correct answer)
3. Continue with aggressive medical management as per the patient's request.
4. Initiate a referral to an inpatient hospice facility.

Explanation: This patient has a very poor prognosis and is suffering from multiple severe complications of end-stage liver disease. While he expresses a desire for 'everything,' this statement may not be based on a full understanding of his prognosis or the burdens and limited benefits of further aggressive treatments. The most appropriate step is to involve the palliative care team to facilitate a comprehensive goals-of-care discussion. This will help the patient and his family understand the clinical situation, explore his values, and make informed decisions about his care that align with those values, which may or may not include 'everything.'

Question 13

1. Acute cellular rejection of the liver allograft.
2. Recurrence of non-alcoholic steatohepatitis.
3. Calcineurin inhibitor-induced nephrotoxicity. (correct answer)
4. Cytomegalovirus (CMV) infection.

Explanation: Tacrolimus is a calcineurin inhibitor (CNI) and a cornerstone of most liver transplant immunosuppression regimens. The most common and significant side effects of CNIs are nephrotoxicity and hypertension. The mechanism involves afferent arteriolar vasoconstriction in the kidney. Given the clinical picture of new-onset hypertension and elevated creatinine with normal liver function tests, CNI toxicity is the most likely diagnosis. Rejection and recurrent NASH would primarily affect liver enzymes, and CMV infection would typically present with other systemic symptoms.

Question 14

1. Perform a percutaneous liver biopsy.
2. Reassure the patient and repeat labs in 6 months.
3. Counsel on diet and exercise as the sole next intervention.
4. Perform a non-invasive vibration-controlled transient elastography (VCTE). (correct answer)

Explanation: When you encounter a patient with diabetes, obesity, and elevated liver enzymes, think non-alcoholic fatty liver disease (NAFLD) and assess for fibrosis progression. The FIB-4 score is a non-invasive tool using age, AST, ALT, and platelets to stratify fibrosis risk. A FIB-4 >2.67 indicates high risk for advanced fibrosis and warrants further evaluation. This patient's FIB-4 of 3.1 puts him in the high-risk category, making additional fibrosis assessment essential. Vibration-controlled transient elastography (VCTE), like FibroScan, is the preferred next step because it's non-invasive, accurate for detecting significant fibrosis, and widely recommended by hepatology guidelines for patients with intermediate-to-high FIB-4 scores. Choice A is incorrect because liver biopsy, while the gold standard, is invasive and reserved for cases where non-invasive methods are inconclusive or when histologic details are specifically needed. Choice B is wrong because a high FIB-4 score demands immediate evaluation—waiting 6 months could allow fibrosis progression in a high-risk patient. Choice C is inadequate because while lifestyle modification is important for NAFLD management, it doesn't address the immediate need to assess current fibrosis severity, which influences treatment urgency and monitoring frequency. Remember this pattern for USMLE Step 3: elevated FIB-4 (>2.67) + clinical risk factors = proceed to VCTE for fibrosis staging. The exam often tests your knowledge of appropriate diagnostic sequencing rather than jumping straight to invasive procedures when non-invasive options exist.

Question 15

1. Transarterial chemoembolization (TACE).
2. Systemic therapy with sorafenib.
3. Surgical resection of the tumor. (correct answer)
4. Stereotactic body radiation therapy (SBRT).

Explanation: According to the Barcelona Clinic Liver Cancer (BCLC) staging system, this patient has Stage A (early-stage) hepatocellular carcinoma. For a single tumor in a patient with preserved liver function and no portal hypertension, surgical resection is a primary curative-intent therapy. Other curative options include liver transplantation or local ablation (radiofrequency or microwave), though ablation is often preferred for tumors <3 cm. TACE is for intermediate-stage disease (BCLC B), and sorafenib is for advanced-stage disease (BCLC C).

Question 16

1. Continue the low-protein diet to prevent future hepatic encephalopathy.
2. Advise a liquid-only diet for two weeks to provide hepatic rest.
3. Recommend a low-fat, low-carbohydrate diet and focus primarily on weight loss.
4. Encourage a daily protein intake of 1.2 to 1.5 g/kg of ideal body weight. (correct answer)

Explanation: When you encounter cirrhosis questions on Step 3, remember that nutritional management has evolved significantly from older practices. The key principle is that protein restriction is only indicated during acute hepatic encephalopathy episodes, not as routine management. This patient with compensated cirrhosis and muscle wasting needs adequate protein intake. Modern hepatology guidelines recommend 1.2-1.5 g/kg of ideal body weight daily for cirrhotic patients without acute encephalopathy. Her fatigue and muscle wasting are classic signs of protein-energy malnutrition, which is common in cirrhosis and actually worsens outcomes. Answer D provides the evidence-based protein target that will help restore her muscle mass and improve her functional status. Answer A perpetuates an outdated approach. Prophylactic protein restriction in stable cirrhosis patients increases malnutrition risk without preventing encephalopathy. Answer B suggests "hepatic rest" through liquid diets - this concept isn't supported by current evidence and would worsen her nutritional status. Answer C focuses on weight loss through macronutrient restriction, but this patient needs adequate nutrition to address her muscle wasting, not further dietary restrictions. The modern understanding is that well-nourished cirrhotic patients tolerate complications better and have improved survival. Protein restriction should only be temporary during acute encephalopathy episodes, then liberalized as tolerated. Step 3 tip: When you see cirrhosis + nutrition questions, ask yourself if the patient currently has encephalopathy. If not, favor adequate protein intake over restriction - the old "low-protein for liver disease" approach is largely outdated except during acute encephalopathic episodes.

Question 17

1. A subdural hematoma from an unwitnessed fall.
2. Progression of alcohol-related dementia.
3. Development of spontaneous bacterial peritonitis.
4. Worsening hepatic encephalopathy from portosystemic shunting. (correct answer)

Explanation: When you encounter a patient with cirrhosis who develops new neurological symptoms after a TIPS procedure, immediately consider hepatic encephalopathy as the primary concern. TIPS (transjugular intrahepatic portosystemic shunt) creates a direct connection between portal and systemic circulation, which can worsen encephalopathy by allowing ammonia and other toxins to bypass hepatic detoxification. This patient's presentation perfectly fits hepatic encephalopathy: confusion, disorientation, asterixis (flapping tremor), and daytime sleepiness occurring weeks after TIPS placement. The timeline is classic - neurological decline following the procedure that successfully treated his ascites but created increased portosystemic shunting. Option A (subdural hematoma) would typically present with focal neurological signs, headache, or evidence of trauma, none of which are described. Option B (alcohol-related dementia) progresses gradually over months to years, not acutely over four weeks. Option C (spontaneous bacterial peritonitis) is unlikely since his ascites has resolved, and SBP typically presents with abdominal pain, fever, and systemic signs of infection rather than isolated neurological symptoms. The correct answer is D because TIPS procedures commonly cause or worsen hepatic encephalopathy in 20-30% of patients by increasing the ammonia load reaching systemic circulation. Despite being on lactulose (which helps reduce ammonia absorption), his encephalopathy has progressed due to the mechanical bypass of liver detoxification. Remember: New neurological symptoms after TIPS = think hepatic encephalopathy first. This is a well-known complication that can occur despite appropriate medical management with lactulose.

Question 18

1. Increase the lactulose dose to achieve four to five bowel movements per day.
2. Add rifaximin to his current lactulose regimen. (correct answer)
3. Advise a strict dietary protein restriction of less than 40 g/day.
4. Refer for TIPS placement to improve liver function.

Explanation: This patient is experiencing recurrent overt hepatic encephalopathy (HE) despite standard first-line therapy with lactulose. In such cases, the addition of rifaximin is the recommended second-line therapy. Rifaximin is a non-absorbable antibiotic that reduces ammonia-producing enteric bacteria and has been shown to reduce the risk of HE recurrence. Further increasing lactulose is likely to cause side effects, protein restriction is contraindicated as it worsens sarcopenia, and TIPS would worsen HE.

Question 19

1. Fresh frozen plasma should be administered to correct the INR to <1.5 before surgery.
2. The elevated INR accurately reflects a severe hypocoagulable state similar to that seen with warfarin.
3. The patient's bleeding risk is more closely associated with the degree of thrombocytopenia than the INR. (correct answer)
4. Both FFP and platelet transfusions are required to minimize the risk of intraoperative bleeding.

Explanation: In cirrhosis, the elevated INR reflects decreased hepatic synthesis of both procoagulant (Factors II, VII, IX, X) and anticoagulant (Protein C, S) factors. This results in a 'rebalanced' hemostasis that the INR does not accurately capture. Clinical bleeding risk in cirrhotic patients undergoing procedures correlates better with the platelet count and function than with the INR. Prophylactic FFP administration to 'correct' the INR is not recommended as it is often ineffective and can cause volume overload.

Question 20

1. Administer IV albumin after large-volume paracentesis (correct answer)
2. Give IV furosemide bolus during the procedure to prevent hypotension
3. Start broad-spectrum antibiotics regardless of ascitic PMN count
4. Restrict all dietary protein for 72 hours to prevent encephalopathy

Explanation: This question tests the management of chronic liver disease and cirrhosis, focusing on clinical decision-making appropriate for independent practice. Chronic liver disease requires careful monitoring and management of complications such as ascites, hepatic encephalopathy, and variceal bleeding. In this vignette, the patient's tense ascites and planned large-volume paracentesis suggest decompensated cirrhosis, requiring immediate assessment and treatment to prevent complications. The correct choice, administering IV albumin after large-volume paracentesis, reflects the appropriate initial management step, aligning with current guidelines for managing cirrhosis and its complications. A common distractor choice, starting broad-spectrum antibiotics regardless of ascitic PMN count, fails because it suggests a non-standard treatment, highlighting a common misconception about liver disease management. To aid learning, emphasize the importance of lifestyle modifications and regular monitoring of liver function to manage and prevent progression of cirrhosis. Encourage the practice of applying standardized guidelines to diverse clinical scenarios.